OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3 kinase alpha harboring the H1047R mutation that is in Phase 1 clinical trial for the treatment of solid tumors, including breast cancer. The company is headquartered in Boulder, Colorado.
Aug 12, 2025, 4:05 PM EDT - 2 months ago
May 6, 2025, 7:30 AM EDT - 5 months ago
Mar 10, 2025, 4:05 PM EDT - 7 months ago
Mar 4, 2025, 8:00 AM EST - 7 months ago
Dec 10, 2024, 7:00 AM EST - 10 months ago
Nov 25, 2024, 5:31 PM EST - 11 months ago
Nov 1, 2024, 5:30 PM EDT - 1 year ago
Oct 24, 2024, 3:31 PM EDT - 1 year ago